Commitments and Contingencies - Collaboration Agreements (Details) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended |
|---|---|---|
Feb. 29, 2020 |
Dec. 31, 2025 |
|
| Commitments and Contingencies | ||
| Non - Refundable aggregate fees payable | $ 1,000 | |
| Non - Refundable upfront fees payable | 500 | |
| Non - Refundable fees payable | 500 | |
| Divestiture fee due to Catalent | 924 | |
| Amount of loss contingency | $ 0 | |
| Common stock | 150,000 | |
| Loss contingency, shares agreed by defendant | 33,836 | 1,692 |
| Target annual bonus | 150.00% | |
| Amended and restated agreement | ||
| Commitments and Contingencies | ||
| Amount payable per product candidate for rare, monogenic disorders | $ 16,500 | |
| Sales milestone payments | 55,000 | |
| Gemma License Agreement | ||
| Commitments and Contingencies | ||
| Amount payable per product candidate for rare, monogenic disorders | 16,500 | |
| Amount payable per product candidate upon achievement of specific development milestone | 39,000 | |
| Sales milestone payments | $ 55,000 |